Evidence map›Paper›PMID 37971237›Full record

ArticleAntimicrobial agents and chemotherapy2023

Silondiwe P Nzimande, Nelesh P Govender, Tsidiso G Maphanga

Open access · greenAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. New Perspectives on Antimicrobial Agents: Fosmanogepix.Antimicrobial agents and chemotherapy · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Silondiwe P NzimandeNational Institute for Communicable Diseases (NICD), a Division of the National Health Laboratory Service, Johannesburg, South Africa.ORCID 0000-0003-2618-8630
Nelesh P GovenderNational Institute for Communicable Diseases (NICD), a Division of the National Health Laboratory Service, Johannesburg, South Africa.ORCID 0000-0001-7869-9462
Tsidiso G MaphangaNational Institute for Communicable Diseases (NICD), a Division of the National Health Laboratory Service, Johannesburg, South Africa.ORCID 0000-0002-6117-4309
National Health Laboratory Service · ZA

Funding

Pfizer Inc. | Pfizer Pharmaceuticals (Pfizer Pharmaceuticals B.V.)
6 · The paper itself

Abstract

We performed

Indexed as

BlastomycesSaccharomyces cerevisiaeAminopyridinesAnimalsAntifungal AgentsHumansIsoxazolesMicrobial Sensitivity TestsOnygenalesSouth AfricaAminopyridinesAntifungal AgentsAPX001AIsoxazolesantifungal susceptibility testingAPX001Ablastomycosisemergomycosismanogepixthermally dimorphic fungi

Identifiers

PMID37971237
PMCPMC10720492
OpenAlexW4388734428

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.